We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




CRP Levels Predict Nosocomial Infections

By HospiMedica staff writers
Posted on 05 May 2006
A new study suggests that daily monitoring of C-reactive protein (CRP) levels could help in the prediction of infections acquired in the intensive care unit.

Dr. More...
Pedro Povoa and colleagues from the Hospital Garcia de Orta (Almada, Portugal) analyzed the CRP levels of patients admitted to their intensive care unit (ICU) during 72 hours or more. Among the patients selected for the study, 35 acquired an infection during their stay at the ICU and 28 did not. Infected patients were those who had a documented ICU-acquired infection and were not receiving antibiotics for at least five days before diagnosis. Noninfected patients never received antibiotics and were discharged. The researchers analyzed the patients' records of CRP levels during the five days before diagnosis of infection or ICU discharge, respectively.

Results showed that a daily variation of CRP levels greater than 4.1 mg/dl is a good marker for prediction of infection, with 92.1% sensitivity and 71.4% specificity. If combined with a CRP concentration greater than 8.7 mg/dl, the prediction power increased even further. Eight-eight percent of patients with a daily variation of CRP levels greater than 4.1 mg/dl and a CRP concentration greater than 8.7 mg/dl developed an infection. Dr. Povoa and coworkers concluded that monitoring CRP progression could help in clinical decision-making and the prescription of antibiotics. The findings were published in the April 2006 issue of the journal Critical Care.

CRP is an acute-phase protein, stably conserved throughout vertebrate evolution, suggesting a central role in immunologic response. It is synthesized in the liver and binds to polysaccharides of pathogens promoting phagocytosis. CRP measurement is a rapid, reproducible, and inexpensive test.

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.